Safety and efficacy of lirentelimab in patients with refractory indolent systemic mastocytosis: a first-in-human clinical trial.

lirentelimab (AK002) - Allakos

http://www.ncbi.nlm.nih.gov/pubmed/37290787

Alan T AT Chang;Andrea M AM Kantor;Bhupinder B Singh;Bradford A BA Youngblood;Edward G EG Michaelis;Frank F Siebenhaar;Hanna H Bonnekoh;Henrik S HS Rasmussen;Marcus M Maurer;Marlena M Hawro;Sabine S Altrichter;Tomasz T Hawro

Jun 9, 2023